Lutetium-177 is integral to this approach due to its favorable decay properties and compatibility with various targeting molecules. The success of targeted radiotherapy in clinical trials and real ...

The production of all n.c.a. Lu-177 depends on a complex and very limited global supply chain which up to now has predominantly been dependent on supply from Russia. Kinectrics is expanding our ...

Lutetium-177 (177 Lu), whose radio-decay characteristics have specific advantages for radiotherapy. The goal is to identify potential carrier molecules that target some of the major cancers for ...

non-carrier-added Lutetium-177 (n.c.a. 177Lu), to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in Radiopharm’s development pipeline.

Romania's Nuclearelectrica and France's Framatome have signed a cooperation agreement on exploring the production of the medical isotope lutetium-177 at the Cernavoda nuclear ... reliable and ...

The production of all n.c.a. Lu-177 depends on a complex and very limited global supply chain which up to now has predominantly been dependent on supply from Russia. Kinectrics is expanding our proven ...